{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:52:08Z","timestamp":1773298328029,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,2,22]],"date-time":"2017-02-22T00:00:00Z","timestamp":1487721600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,2,22]],"date-time":"2017-02-22T00:00:00Z","timestamp":1487721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>There is no definitive conclusion regarding the optimal timing for terminating propranolol treatment for infantile hemangioma (IH). A total of 149 patients who underwent detailed color Doppler ultrasound examination were included in this study. The characteristics and propranolol treatment of all patients were summarized and analyzed. Patients were divided into two groups according to the lesion regression rate. Among the 149 patients, 38 were assigned to the complete regression group, and 111 were assigned to the partial regression group. The age at which propranolol treatment started, duration of follow-up after treatment discontinuation and rate of adverse events were not significantly different between the two groups. The duration of oral propranolol treatment was shorter in the complete regression group. The age at which propranolol was terminated was younger in the complete regression group, and this group had a lower recurrence rate. Propranolol is safe and effective for the treatment of IHs that require intervention, but it should be stopped at an appropriate time, which is determined primarily by the lesion regression rate after propranolol treatment. Ultrasound is helpful in determining when to stop propranolol for IH.<\/jats:p>","DOI":"10.1038\/srep43292","type":"journal-article","created":{"date-parts":[[2017,2,22]],"date-time":"2017-02-22T11:42:40Z","timestamp":1487763760000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["When to stop propranolol for infantile hemangioma"],"prefix":"10.1038","volume":"7","author":[{"given":"Lei","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifei","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanru","family":"Ying","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yajing","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunbo","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,2,22]]},"reference":[{"key":"BFsrep43292_CR1","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/j.1525-1470.2008.00626.x","volume":"25","author":"C Kilcline","year":"2008","unstructured":"Kilcline, C. & Frieden, I. J. Infantile hemangiomas: how common are they? A systematic review of the medical literature. Pediatr Dermatol. 25(2), 168\u2013173 (2008).","journal-title":"Pediatr Dermatol."},{"key":"BFsrep43292_CR2","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1404710","volume":"372","author":"C L\u00e9aut\u00e9-Labr\u00e9ze","year":"2015","unstructured":"L\u00e9aut\u00e9-Labr\u00e9ze, C., Hoeger, P. & Mazereeuw-Hautier, J. A randomized controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 372(8), 518\u2013519 (2015).","journal-title":"N Engl J Med"},{"key":"BFsrep43292_CR3","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/SCS.0000000000002206","volume":"27","author":"ZM Maclsaac","year":"2016","unstructured":"Maclsaac, Z. M. et al. Treatment for infantile hemangiomas: selection criteria, safety, and outcomes using oral propranolol during the early phase of propranolol use for hemangiomas. J Craniofac Surg 27(1), 159\u201362 (2016).","journal-title":"J Craniofac Surg"},{"key":"BFsrep43292_CR4","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1007\/s00247-016-3643-6","volume":"46","author":"D Menapace","year":"2016","unstructured":"Menapace, D. et al. The changing face of complicated infantile hemangioma treatment. Pediatri Radiol 46(11), 1494\u2013506 (2016).","journal-title":"Pediatri Radiol"},{"key":"BFsrep43292_CR5","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s00431-015-2570-0","volume":"174","author":"PH Hoeger","year":"2015","unstructured":"Hoeger, P. H. et al. Treatment of infantile haemangiomas: recommendations of a European expert group. European journal of pediatrics 174(7), 855\u2013865 (2015).","journal-title":"European journal of pediatrics"},{"key":"BFsrep43292_CR6","first-page":"1632","volume":"144","author":"HA Brandlingbennett","year":"2008","unstructured":"Brandlingbennett, H. A. et al. Infantile hemangiomas with unusually prolonged growth phase: a case series. Arch Dermatol. 144(12), 1632\u20137 (2008).","journal-title":"Arch Dermatol."},{"key":"BFsrep43292_CR7","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1542\/peds.2015-2485","volume":"136","author":"DH Darrow","year":"2015","unstructured":"Darrow, D. H. et al. Diagnosis and management of infantile hemangioma. Pediatrics. 136(4), 1060\u2013104 (2015).","journal-title":"Pediatrics"},{"key":"BFsrep43292_CR8","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/S0022-3468(83)80043-8","volume":"18","author":"MC Finn","year":"1983","unstructured":"Finn, M. C., Glowacki, J. & Mulliken, J. B. Congenital vascular lesions: clinical application of a new classification. J Pediatr Surg. 18(6), 894\u2013900 (1983).","journal-title":"J Pediatr Surg"},{"key":"BFsrep43292_CR9","first-page":"851","volume":"6","author":"WZ Jia","year":"2013","unstructured":"Jia, W. Z. et al. A practical guide to treatment of infantile hemangiomas of the head and neck. Int J Clin Exp Med. 6(10), 851\u201360 (2013).","journal-title":"Int J Clin Exp Med"},{"key":"BFsrep43292_CR10","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1056\/NEJMc1503811","volume":"373","author":"A Tozzi","year":"2015","unstructured":"Tozzi, A. Oral propranolol for infantile hemangioma. N Engl J Med. 373(3), 284 (2015).","journal-title":"N Engl J Med"},{"key":"BFsrep43292_CR11","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.jaad.2015.04.053","volume":"73","author":"AV Moyakine","year":"2015","unstructured":"Moyakine, A. V., Hermans, D. J. J. & Fuijkschot, J. Propranolol treatment of infantile hemangiomas does not negatively affect psychomotor development. J Am Acad Dermatol, 73(2), 341\u20132 (2015).","journal-title":"J Am Acad Dermatol"},{"key":"BFsrep43292_CR12","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/pde.12190","volume":"30","author":"N Shehata","year":"2013","unstructured":"Shehata, N. et al. Late rebound of infantile hemangioma after cessation of oral propranolol. Pediatr Dermatol. 30(5), 587\u201391 (2013).","journal-title":"Pediatr Dermatol."},{"key":"BFsrep43292_CR13","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1159\/000351557","volume":"228","author":"L Sagi","year":"2014","unstructured":"Sagi, L. et al. Efficacy and safety of propranolol for the treatment of infantile hemangioma: a presentation of ninety-nine cases. Dermatology 228(2), 136\u201344 (2014).","journal-title":"Dermatology"},{"issue":"5","key":"BFsrep43292_CR14","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/SAP.0000000000000506","volume":"76","author":"Lei Chang","year":"2016","unstructured":"Chang, L. et al. Is propranolol safe and effective for outpatient use for infantile hemangioma? a prospective study of 679 cases from one center in china. Ann Plast Surg. 76(5) (2015).","journal-title":"Annals of Plastic Surgery"},{"key":"BFsrep43292_CR15","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1097\/PRS.0000000000000007","volume":"133","author":"P Szychta","year":"2014","unstructured":"Szychta, P., Stewart, K. & Anderson, W. Treatment of infantile hemangiomas with propranolol: clinical guidelines. Plast Reconstr Surg. 133(4), 852\u201362 (2014).","journal-title":"Plast Reconstr Surg"},{"key":"BFsrep43292_CR16","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.bjps.2010.06.010","volume":"64","author":"ST Tan","year":"2011","unstructured":"Tan, S. T., Itinteang, T. & Leadbitter, P. Low-dose propranolol for infantile haemangioma. J Plast Reconstr Aesthet Surg. 64(3), 292\u20139 (2011).","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"BFsrep43292_CR17","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/j.ophtha.2010.10.031","volume":"118","author":"RA Dhaybi","year":"2011","unstructured":"Dhaybi, R. A. et al. Treatment of periocular infantile hemangiomas with propranolol: case series of 18 children. Ophthalmology. 118(6), 1184\u20138 (2011).","journal-title":"Ophthalmology"},{"key":"BFsrep43292_CR18","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.bjps.2010.07.009","volume":"64","author":"WJM Holmes","year":"2011","unstructured":"Holmes, W. J. M. et al. Propranolol as first-line treatment for rapidly proliferating infantile haemangiomas. J Plast Reconstr Aesthet Surg. 64(4), 445\u201351 (2011).","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"BFsrep43292_CR19","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.jpedsurg.2011.10.058","volume":"47","author":"AA Talaat","year":"2012","unstructured":"Talaat, A. A. et al. Propranolol treatment of infantile hemangioma: clinical and radiologic evaluations. J Pediatr Surg. 47(4), 707\u201314 (2012).","journal-title":"J Pediatr Surg"},{"key":"BFsrep43292_CR20","first-page":"2138","volume":"8","author":"ZG Chen","year":"2014","unstructured":"Chen, Z. G. et al. A survey on clinical use of propranolol for infantile hemangiomas in mainland china. Int J Clin Exp Med. 8(2), 2138\u201346 (2014).","journal-title":"Int J Clin Exp Med"},{"key":"BFsrep43292_CR21","doi-asserted-by":"crossref","unstructured":"Hermans, D. J. J. et al. Propranolol in a case series of 174 complicated infantile haemangioma patients: indications, safety and future directions. Br J Dermatol. 168(4) (2012).","DOI":"10.1111\/bjd.12189"},{"key":"BFsrep43292_CR22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1177\/229255031302100103","volume":"21","author":"Sharma","year":"2012","unstructured":"Sharma et al. Beta-blockers for the treatment of problematic hemangiomas. Can J Plast Surg. 21(1), 23\u20138 (2012).","journal-title":"Can J Plast Surg"},{"issue":"9","key":"BFsrep43292_CR23","doi-asserted-by":"publisher","first-page":"e0138100","DOI":"10.1371\/journal.pone.0138100","volume":"10","author":"Xiaohan Liu","year":"2015","unstructured":"Liu, X. et al. Effectiveness and safety of oral propranolol versus other treatments for infantile hemangiomas: a meta-analysis. Plos One. 10(9) (2015).","journal-title":"PLOS ONE"},{"key":"BFsrep43292_CR24","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1056\/NEJM198903023200905","volume":"320","author":"HH Zhou","year":"1989","unstructured":"Zhou, H. H. et al. Altered sensitivity to and clearance of propranolol in men of chinese descent as compared with american whites. N Engl J Med. 320(9), 565\u201370 (1989).","journal-title":"N Engl J Med"},{"key":"BFsrep43292_CR25","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/j.1525-1470.2011.01498.x","volume":"28","author":"DR Berk","year":"2011","unstructured":"Berk, D. R., Berk, E. J. & Bruckner, A. L. A novel method for calculating the volume of hemangiomas. Pediatr Dermatol. 28(4), 478\u201382 (2011).","journal-title":"Pediatr Dermatol"},{"key":"BFsrep43292_CR26","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1016\/j.ultrasmedbio.2014.06.021","volume":"40","author":"H Shi","year":"2014","unstructured":"Shi, H. et al. Ultrasound in assessing the efficacy of propranolol therapy for infantile hemangiomas. Ultrasound Med Biol. 40(11), 2622\u20132629 (2014).","journal-title":"Ultrasound Med Biol"},{"key":"BFsrep43292_CR27","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jaad.2009.06.016","volume":"62","author":"X Wortsman","year":"2010","unstructured":"Wortsman, X. & Wortsman, J. Clinical usefulness of variable-frequency ultrasound in localized lesions of the skin. J Am Acad Dermatol. 62(2), 247\u201356 (2010).","journal-title":"J Am Acad Dermatol"},{"key":"BFsrep43292_CR28","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1177\/0194599812451570","volume":"147","author":"MM Bingham","year":"2012","unstructured":"Bingham, M. M. et al. Propranolol reduces infantile hemangioma volume and vessel density. Otolaryngol Head Neck Surg. 147(2), 338\u2013344 (2012).","journal-title":"Otolaryngol Head Neck Surg"},{"key":"BFsrep43292_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jpeds.2010.08.013","volume":"157","author":"A Fay","year":"2010","unstructured":"Fay, A., Nguyen, J. & Waner, M. Conceptual approach to the management of infantile hemangiomas. J Pediatr. 157(6), 1\u20135 (2010).","journal-title":"J Pediatr."},{"key":"BFsrep43292_CR30","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jaad.2016.02.1218","volume":"75","author":"AV Moyakine","year":"2016","unstructured":"Moyakine, A. V., Kerstjens, J. M. & Koulil, S. V. Propranolol treatment of infantile hemangioma (ih) is not associated with developmental risk or growth impairment at age 4years. J Am Acad Dermatol. 75(1), 59\u201363 (2016).","journal-title":"J Am Acad Dermatol"},{"issue":"24","key":"BFsrep43292_CR31","doi-asserted-by":"publisher","first-page":"e3908","DOI":"10.1097\/MD.0000000000003908","volume":"95","author":"Yi Ji","year":"2016","unstructured":"Ji, Y. et al. Oral atenolol therapy for proliferating infantile hemangioma: a prospective study. Medicine 95(24) (2016).","journal-title":"Medicine"},{"key":"BFsrep43292_CR32","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1056\/NEJMc086443","volume":"359","author":"EC Siegfried","year":"2008","unstructured":"Siegfried, E. C., Keenan, W. J. & Al-Jureidini, S. More on propranolol for hemangiomas of infancy. N Engl J Med. 359(26), 2846\u20137 (2008).","journal-title":"N Engl J Med"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep43292.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep43292","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep43292.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,24]],"date-time":"2022-12-24T01:11:32Z","timestamp":1671844292000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep43292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,22]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,4,10]]}},"alternative-id":["BFsrep43292"],"URL":"https:\/\/doi.org\/10.1038\/srep43292","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,22]]},"assertion":[{"value":"13 October 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43292"}}